Zim Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Zim Laboratories Ltd reported a 1.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.9%.
• Its expenses for the quarter were up by 2.1% QoQ and 4.1% YoY.
• The net profit decreased 15.0% QoQ and decreased 23.4% YoY.
• The earnings per share (EPS) of Zim Laboratories Ltd stood at 0.76 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Zim Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and sale of pharmaceutical products. The company specializes in innovative drug delivery solutions and offers a range of products, including oral solid dosage forms, which are a significant part of its portfolio. Zim Laboratories is known for its focus on research and development, striving to deliver high-quality and effective healthcare solutions. As of the latest update in October 2023, there have been no major developments publicly reported for the company.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Zim Laboratories Ltd reported a total income of ₹111.44 crores. This reflects a quarter-over-quarter (QoQ) increase of 1.0% from ₹110.36 crores in Q3FY26 and a year-over-year (YoY) increase of 0.9% from ₹110.44 crores in Q4FY25. The growth in total income indicates consistent revenue generation over the past year. While the increase is modest, it demonstrates the company's ability to maintain a stable income stream in a competitive market.

Profitability

During Q4FY26, Zim Laboratories Ltd reported a profit before tax of ₹4.94 crores, reflecting a decrease of 18.3% QoQ from ₹6.05 crores in Q3FY26 and a significant decline of 39.1% YoY from ₹8.11 crores in Q4FY25. After accounting for taxes, the profit after tax stood at ₹3.74 crores, down by 15.0% QoQ and 23.4% YoY. The earnings per share (EPS) for the quarter was ₹0.76, which represents a decrease of 15.6% QoQ and 24.8% YoY. These figures indicate a downward trend in profitability despite stable revenue, which could be attributed to increased expenses.

Operating Metrics

Total expenses for Zim Laboratories Ltd in Q4FY26 were ₹106.49 crores, representing a 2.1% increase QoQ from ₹104.31 crores in Q3FY26 and a 4.1% increase YoY from ₹102.34 crores in Q4FY25. The increase in expenses has outpaced the growth in total income, which has impacted the company's profitability metrics. The tax expense for Q4FY26 was ₹1.20 crores, a reduction of 27.3% QoQ and a significant decrease of 62.7% YoY, which suggests an adjustment in the company's tax liabilities. Despite the increase in expenses, the company has managed to reduce its tax burden, contributing to the retained earnings.